Altimmune Inc (ALT)
4.23
+0.05
(+1.20%)
USD |
NASDAQ |
Mar 23, 12:40
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 208.45M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -40.20% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.125 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.85% |
News
Headline
Wire
Time (ET)
MT Newswires
03/22 07:25
SA Breaking News
03/21 18:40
SA Breaking News
03/21 10:03
Globe Newswire
03/21 07:00
SA Breaking News
03/10 15:00
Globe Newswire
02/28 07:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/12/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/12/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 02/28/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | -0.44 | -0.54 | 17.91% | |
| 11/10/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/10/2022 | -- | Results | Q3 2022 | -0.48 | -0.51 | 5.42% | |
| 08/11/2022 | -- | Results | Q2 2022 | -0.42 | -0.50 | 15.15% | |
| 08/11/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines. |
| URL | https://www.altimmune.com |
| Investor Relations URL | https://ir.altimmune.com/ |
| HQ State/Province | Maryland |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 20, 2017 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | Jan. 20, 2017 |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 22, 2023.
Fundamentals
| Revenue (TTM) | -0.068M |
| Total Expenses (TTM) | 87.67M |
| Net Income (TTM) | -84.71M |
| Total Assets (Quarterly) | 206.93M |
| Total Liabilities (Quarterly) | 21.64M |
| Shareholders Equity (Quarterly) | 185.29M |
| Cash from Operations (TTM) | -62.59M |
| Cash from Investing (TTM) | -73.40M |
| Cash from Financing (TTM) | 56.78M |
Ratings
Profile
Edit
| Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company’s pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines. |
| URL | https://www.altimmune.com |
| Investor Relations URL | https://ir.altimmune.com/ |
| HQ State/Province | Maryland |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 20, 2017 |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALT Tweets |